Santhera completes FJORD enrollment
Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company focused on orphan neuromuscular diseases, has closed the recruitment for its confirmatory Phase IIb FJORD study with JP-1730 (fipamezole) in Parkinson's disease dyskinesia.
The double-blind, randomized, placebo-controlled dose-escalation study evaluates the safety and efficacy of three doses of fipamezole compared to placebo over a treatment period of 28 days. A total of 180 patients have now been recruited and, with the current lower-than-expected drop-out rate, the target of 120 evaluable patients in the database will be exceeded. Top-line results from the study are expected in the third quarter of 2009.
Chief executive Klaus Schollmeier said: "we believe that the FJORD study will demonstrate the drug's efficacy and provide critical information for the late-stage development of JP-1730/fipamezole in order to make it available as quickly as possible to the benefit of Parkinson's sufferers."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze